Ticagrelor

Generic Name: Ticagrelor

Brand Names: Brilinta, Brilique

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₈F_₂N_₆O_₄S

CAS Number: 274693-27-5

Unique Ingredient Identifier: GLH0314RVC

Background: Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.

Ticagrelor was granted EMA approval on 3 December 2010.

Ticagrelor was granted FDA approval on 20 July 2011.

Indication: Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.

Associated Conditions: Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)

Associated Therapies: -

Clinical Trials

Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation

Phase 4

Completed

Conditions: Plaque, Atherosclerotic

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2013-07-23

Last Posted Date: 2016-02-26

Lead Sponsor: CHEOL WHAN LEE, M.D., Ph.D

Target Recruit Count: 50

Registration Number: NCT01905566

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2013-07-10

Last Posted Date: 2017-04-24

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 36

Registration Number: NCT01894789

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

Phase 1

Completed

Conditions: Community Acquired Pneumonia
Hospital Acquired Pneumonia
Pneumonia
Acute Lung Injury

Interventions: Drug: placebo
Drug: ticagrelor

First Posted Date: 2013-06-21

Last Posted Date: 2018-09-13

Lead Sponsor: University of Kentucky

Target Recruit Count: 60

Registration Number: NCT01883869

Locations: 🇺🇸
University of Kentucky Hospitals, Lexington, Kentucky, United States
🇺🇸
University of Kentucky Hospital, Lexington, Kentucky, United States

Brilinta DaYu Study

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor

First Posted Date: 2013-06-06

Last Posted Date: 2018-04-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 2004

Registration Number: NCT01870921

Locations: 🇨🇳
Research Site, Zhongshan, China

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

Phase 4

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2013-06-05

Last Posted Date: 2014-11-21

Lead Sponsor: LifeBridge Health

Target Recruit Count: 400

Registration Number: NCT01869309

Locations: 🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States

A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS

Phase 4

Completed

Conditions: Non-ST or ST Elevation Acute Coronary Syndromes

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2013-05-29

Last Posted Date: 2015-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 60

Registration Number: NCT01864005

Locations: 🇨🇳
Research Site, Tianjin, China

Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

Not Applicable

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2013-05-13

Last Posted Date: 2015-06-10

Lead Sponsor: University of Florida

Target Recruit Count: 110

Registration Number: NCT01852175

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

Not Applicable

Completed

Conditions: Diabetes Mellitus
Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2013-05-13

Last Posted Date: 2016-10-17

Lead Sponsor: University of Florida

Target Recruit Count: 50

Registration Number: NCT01852214

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

The Antiplatelet and Immune Response Trial

Phase 4

Completed

Conditions: Healthy

Interventions: Biological: Endotoxin
Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2013-05-03

Last Posted Date: 2021-09-27

Lead Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 30

Registration Number: NCT01846559

Locations: 🇬🇧
Sheffield Clinical Research Facility, Sheffield, South Yorkshire, United Kingdom

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Phase 3

Completed

Conditions: Percutaneous Coronary Intervention
Atrial Fibrillation

Interventions: Drug: rivaroxaban 2.5 mg
Drug: rivaroxaban 15 mg
Drug: rivaroxaban 10 mg
Drug: vitamin K antagonist (VKA)
Drug: aspirin (ASA)
Drug: clopidogrel
Drug: prasugrel
Drug: ticagrelor

First Posted Date: 2013-04-12

Last Posted Date: 2017-09-19

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 2124

Registration Number: NCT01830543

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy